Ownership and insider activity for ProKidney Corp. (PROK): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease.
Price
| Price | $1.85 |
| Market Cap | $622M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-18 | Pereira Brian JG | S-Sale | 229,338 | $314K |
| 2026-08-19 | Pereira Brian JG | S-Sale | 222,949 | $321K |
| 2026-08-18 | Pereira Brian JG | S-Sale | 27,826 | $38K |
| 2026-08-19 | Pereira Brian JG | S-Sale | 27,051 | $39K |
| 2026-08-20 | Pereira Brian JG | S-Sale | 27,052 | $38K |
| 2026-08-04 | Pereira Brian JG | C-Conversion | 675,235 | |
| 2026-08-04 | Pereira Brian JG | C-Conversion | 81,929 | |
| 2026-08-04 | Pereira Brian JG | C-Conversion | 675,235 | |
| 2026-08-04 | Pereira Brian JG | C-Conversion | 675,235 | |
| 2026-07-01 | Locke Kenneth Thomas | A-Award | 750,000 | $1.4M |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.2M | $4.6M | $20.6M | $490.3M | $60.6M | $99.1M | $108.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | $302.3M | $259.2M | $161.5M |
| Receivables | 0 | 0 | 0 | 0 | $1.4M | $2.4M | $1.1M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $15.4M | $5.6M | $27.3M | $504.7M | $374.1M | $395.9M | $280.7M |
| Property, Plant & Equipment | $3.3M | $10.5M | $12.6M | $13.1M | $46.4M | $45.2M | $54.9M |
| Goodwill | 0 | $641358 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $857000 | $642 | $428000 | $213000 | 0 | 0 | 0 |
| Total Assets | $19.6M | $16.7M | $40.3M | $518.0M | $420.6M | $441.1M | $335.6M |
| Accounts Payable | $480000 | $781000 | $2.8M | $3.0M | $5.1M | $3.6M | $940000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.7M | $5.5M | $12.3M | $10.9M | $25.0M | $36.2M | $30.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $3.7M | $6.8M | $13.4M | $13.1M | $29.2M | $39.4M | $34.8M |
| Retained Earnings | -$79.6M | -$106.4M | -$161.5M | -$1.10B | -$1.14B | -$1.20B | -$1.27B |
| Total Equity | $15.9M | $9.9M | $26.9M | -$1.10B | -$1.10B | -$995.0M | -$1.01B |
| Total Debt | $1.1M | $1.6M | $1.3M | $2.4M | $4.4M | $3.2M | $4.0M |
| Net Debt | -$14.1M | -$3.0M | -$19.2M | -$487.9M | -$358.5M | -$355.1M | -$266.0M |
| Working Capital | $12.7M | $83000 | $15.0M | $493.8M | $349.1M | $359.7M | $249.9M |
Financial Health
| Debt / Equity | -0.00 |
| Current Ratio | 8.36 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 5.72 |
Profitability
| Return on Equity | 8.83% |
| Return on Invested Capital | -68.08% |
| Return on Assets | -34.82% |
| Gross Margin | -252.57% |
| Operating Margin | -21664.55% |
| Net Margin | -10599.76% |
Related companies: BCAX · EYPT · KURA · NBTX · PRME · RZLT · SEPN
Explore sector: Healthcare · Biotechnology
More sections of PROK: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks